Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications
Tier: Tier 1

1. A 67-year-old man with hypertension, type 2 diabetes, and stage 3a CKD (eGFR 52 mL/min/1.73m²) has a urine ACR of 210 mg/g. His BP is 152/88 mmHg on amlodipine 10 mg. His potassium is 4.4 mEq/L. Which of the following is the most appropriate addition to his regimen?

A) Hydrochlorothiazide 25 mg — volume reduction will lower BP and reduce the glomerular filtration driving proteinuria through a purely hemodynamic mechanism
B) Spironolactone — mineralocorticoid receptor antagonism provides renoprotection superior to RAAS inhibition in diabetic CKD and avoids the hyperkalemia risk of ACE inhibitors
C) Metoprolol succinate — beta-1 blockade reduces renin secretion and cardiac output, providing additional BP lowering without affecting renal hemodynamics
D) An ACE inhibitor or ARB — RAAS inhibition reduces intraglomerular pressure through efferent arteriolar dilation, decreases proteinuria, and has established evidence for slowing CKD progression in diabetic nephropathy with albuminuria; his potassium of 4.4 mEq/L and eGFR of 52 are acceptable starting points with close monitoring
E) Clonidine — central sympatholysis reduces renal sympathetic tone which is the primary driver of proteinuria in diabetic nephropathy

ANSWER: D

Rationale:

The combination of hypertension, type 2 diabetes, and albuminuria (ACR 210 mg/g) constitutes a compelling indication for RAAS inhibition — ACE inhibitors and ARBs reduce efferent arteriolar tone, lowering intraglomerular hydraulic pressure and decreasing proteinuria through a mechanism independent of systemic BP reduction; landmark trials (RENAAL, IDNT, MICRO-HOPE) demonstrated slowed CKD progression with RAAS inhibition in this population; his potassium of 4.4 mEq/L and eGFR of 52 mL/min are acceptable for initiating RAAS blockade with close monitoring of potassium and creatinine.

Option A: Option A is incorrect — thiazides reduce BP but do not provide the specific intraglomerular pressure reduction and antiproteinuric benefit of RAAS inhibition; they are useful as add-on therapy but not the priority addition here.
Option C: Option C is incorrect — beta-blockers provide additional BP lowering but lack the specific renoprotective mechanism of RAAS inhibition in diabetic nephropathy; they are not the preferred addition in this clinical context.
Option B: Option B is incorrect — spironolactone has emerging renoprotective evidence (finerenone in FIDELIO-DKD) but is not established as superior to RAAS inhibition; hyperkalemia risk with spironolactone on top of CKD is significant without a kaliuretic agent.
Option E: Option E is incorrect — central sympatholysis is not the primary driver of proteinuria reduction in diabetic nephropathy; clonidine does not have renoprotective evidence in this indication.

2. A 54-year-old woman with hypertension is started on lisinopril 10 mg. Two weeks later she presents with progressive facial swelling involving her lips and tongue over the past 6 hours. She has no urticaria or pruritus. Her BP is 138/86 mmHg. Which of the following most accurately describes the management of this presentation?

A) Administer diphenhydramine and continue lisinopril at a reduced dose — the swelling is an allergic reaction that will respond to antihistamine therapy and does not require drug discontinuation
B) Discontinue lisinopril immediately and treat the angioedema — bradykinin-mediated angioedema does not respond reliably to epinephrine, antihistamines, or corticosteroids because histamine is not the mediator; airway management is the priority; all ACE inhibitors are permanently contraindicated; when an antihypertensive is needed, an ARB may be considered but carries a small cross-reactivity risk and should be used with caution and informed consent
C) Switch to a higher dose of lisinopril — the swelling indicates an inadequate drug response and dose escalation is needed
D) Administer epinephrine and restart lisinopril once the swelling resolves — ACE inhibitor angioedema is a one-time event and recurrence is not expected with continued use
E) Switch immediately to an ARB — ARBs are pharmacologically identical to ACE inhibitors and carry no angioedema risk whatsoever, making the transition completely safe

ANSWER: B

Rationale:

ACE inhibitor angioedema is a medical emergency — the facial and tongue swelling without urticaria or pruritus is classic bradykinin-mediated angioedema, distinct from IgE-mediated allergic reactions; bradykinin-mediated angioedema does not respond reliably to epinephrine, antihistamines, or corticosteroids because histamine is not the mediator; airway management is the priority as laryngeal involvement can cause fatal obstruction; all ACE inhibitors are permanently contraindicated after this event; ARBs carry a small cross-reactivity risk (approximately 10% in some series) and if used should be initiated with informed consent and close monitoring; icatibant (a bradykinin B2 receptor antagonist) or C1-esterase inhibitor concentrate are emerging treatment options for severe bradykinin-mediated angioedema.

Option A: Option A is incorrect — antihistamines do not treat bradykinin-mediated angioedema and continuing the drug risks life-threatening airway compromise.
Option C: Option C is incorrect — this is an adverse drug reaction requiring immediate discontinuation, not a therapeutic inadequacy.
Option D: Option D is incorrect — ACE inhibitor angioedema is a permanent class contraindication; recurrence with continued use is expected and potentially fatal.
Option E: Option E is incorrect — ARBs do carry a small but real cross-reactivity risk for angioedema; characterizing them as completely safe is inaccurate and potentially dangerous.

3. A 72-year-old man with hypertension, benign prostatic hyperplasia (BPH) causing significant lower urinary tract symptoms, and no other cardiovascular comorbidities has BP of 158/92 mmHg on chlorthalidone 25 mg. His urologist suggests adding doxazosin for his BPH symptoms. His cardiologist needs to consider the cardiovascular implications. Which of the following most accurately describes the pharmacological considerations?

A) Doxazosin is an excellent antihypertensive choice here — it provides dual benefit for both hypertension and BPH through alpha-1 blockade; ALLHAT demonstrated cardiovascular outcomes with doxazosin equivalent to chlorthalidone making it an appropriate addition
B) Doxazosin may provide symptomatic benefit for BPH through alpha-1 blockade of prostatic smooth muscle but should not be relied upon as an antihypertensive agent — the ALLHAT trial demonstrated that doxazosin was inferior to chlorthalidone for heart failure prevention; additionally, combining doxazosin with chlorthalidone risks significant orthostatic hypotension particularly in a 72-year-old; if added for BPH, BP should be monitored closely and the chlorthalidone dose may need adjustment
C) Alpha-1 blockers are absolutely contraindicated in patients over 70 because orthostatic hypotension risk in elderly patients makes them uniformly dangerous regardless of indication
D) Doxazosin is preferred over chlorthalidone for hypertension in elderly men with BPH — it should replace chlorthalidone rather than be added to it to avoid the additive hypotensive risk
E) The ALLHAT trial demonstrated that alpha-1 blockers are superior to thiazide diuretics for cardiovascular protection in elderly men and doxazosin should be substituted for chlorthalidone in this patient

ANSWER: B

Rationale:

Doxazosin has legitimate urological benefit — alpha-1 receptor blockade in prostatic smooth muscle and the bladder neck reduces outflow obstruction and improves lower urinary tract symptoms in BPH; however, its cardiovascular profile is less favorable than other antihypertensive classes; ALLHAT demonstrated that doxazosin was inferior to chlorthalidone specifically for heart failure prevention (the doxazosin arm was stopped early for this reason); orthostatic hypotension is a significant risk, particularly when combined with a diuretic in an elderly patient; if added for BPH, the combination requires careful BP monitoring and the patient should be counseled about orthostatic precautions.

Option A: Option A is incorrect — ALLHAT specifically showed doxazosin inferior to chlorthalidone for heart failure; characterizing outcomes as equivalent is factually wrong.
Option C: Option C is incorrect — alpha-1 blockers are not absolutely contraindicated in the elderly; they are used cautiously with appropriate monitoring and orthostatic precautions; this is a relative concern, not an absolute contraindication.
Option D: Option D is incorrect — replacing chlorthalidone (which has strong outcome evidence) with doxazosin (which has inferior cardiovascular outcome data) would be pharmacologically unsound.
Option E: Option E is incorrect — ALLHAT demonstrated the opposite; doxazosin was inferior to chlorthalidone for cardiovascular outcomes.

4. A 48-year-old woman with hypertension and no other comorbidities is well-controlled on enalapril 10 mg twice daily. She is 8 weeks pregnant. Which of the following most accurately describes the required management change?

A) Discontinue enalapril immediately and switch to a pregnancy-safe antihypertensive — methyldopa, labetalol, or extended-release nifedipine are the established alternatives; ACE inhibitors cause fetal renal tubular dysplasia, oligohydramnios, and calvarial ossification defects through fetal RAAS blockade; these risks apply throughout pregnancy and the drug must be stopped without delay
B) Reduce the enalapril dose by half — lower doses of ACE inhibitors are safe in pregnancy because fetal drug exposure is proportional to maternal dose
C) Continue enalapril through the first trimester — fetal RAAS blockade is only harmful from 16 weeks onward when the fetal kidneys become functional; first-trimester exposure is safe
D) Switch to an ARB — ARBs are safe in pregnancy because they block only the AT1 receptor while sparing the AT2 receptor that mediates normal fetal development
E) Continue enalapril and add folic acid supplementation — folic acid counteracts the teratogenic effects of ACE inhibitors by restoring normal folate-dependent developmental pathways

ANSWER: A

Rationale:

ACE inhibitors are contraindicated throughout pregnancy — the fetal RAAS is active from early gestation; enalapril must be discontinued immediately at 8 weeks; safe alternatives with established pregnancy track records include methyldopa (oldest and best-studied), labetalol (combined alpha/beta blocker widely used in pregnancy), and extended-release nifedipine (dihydropyridine CCB with good safety data); the fetal toxicity of ACE inhibitors is through RAAS blockade causing renal tubular dysplasia, reduced fetal urine output, oligohydramnios, and secondary pulmonary hypoplasia and calvarial ossification defects; this is not dose-dependent and cannot be mitigated by dose reduction.

Option C: Option C is incorrect — the old guidance suggesting first-trimester safety has been revised; fetal RAAS is active from early gestation and exposure at 8 weeks is not safe; the drug must be stopped immediately.
Option B: Option B is incorrect — the teratogenic mechanism is pharmacological RAAS blockade, which occurs at any therapeutic dose; dose reduction does not make ACE inhibitors safe in pregnancy.
Option D: Option D is incorrect — ARBs are equally contraindicated in pregnancy; they block fetal RAAS through AT1 receptor blockade and cause the same fetal toxicity as ACE inhibitors; AT2 receptor sparing does not protect fetal renal development.
Option E: Option E is incorrect — folic acid does not counteract ACE inhibitor fetal toxicity; the mechanism is pharmacological RAAS blockade, not folate-dependent teratogenicity.

5. A 61-year-old man with hypertension and a recent anterior STEMI (6 weeks ago, treated with PCI, EF now 42%) has BP of 146/88 mmHg. He is currently on aspirin, atorvastatin, and clopidogrel. Which antihypertensive regimen is most pharmacologically appropriate?

A) Amlodipine monotherapy — dihydropyridine CCBs are the preferred post-MI antihypertensive because they reduce cardiac workload through afterload reduction without the bradycardic risk of beta-blockers in a recently infarcted heart
B) Chlorthalidone monotherapy — thiazide diuretics are preferred post-MI because volume reduction reduces preload and wall stress in the remodeling ventricle
C) An ARB as monotherapy — ARBs are preferred over ACE inhibitors post-MI because they provide superior ventricular remodeling benefit without the cough side effect that reduces adherence
D) An ACE inhibitor plus a beta-blocker — both classes have mortality benefit in post-MI patients with reduced EF; ACE inhibitors reduce adverse ventricular remodeling and improve survival (SAVE, AIRE trials); beta-blockers reduce reinfarction risk, ventricular arrhythmias, and mortality (MERIT-HF, CAPRICORN); together they address BP and provide evidence-based post-MI cardioprotection
E) Verapamil — non-dihydropyridine CCBs are specifically indicated post-MI with reduced EF because their negative chronotropy reduces myocardial oxygen demand more effectively than beta-blockers

ANSWER: D

Rationale:

Post-MI with reduced EF (42%) is a compelling indication for both ACE inhibitors and beta-blockers — ACE inhibitors prevent adverse ventricular remodeling, reduce heart failure progression, and improve mortality post-MI (SAVE trial with captopril, AIRE trial with ramipril); beta-blockers reduce sympathetic activation, prevent ventricular arrhythmias, reduce reinfarction risk, and improve mortality (CAPRICORN with carvedilol post-MI with LV dysfunction); the combination addresses both BP and the post-MI cardioprotection that evidence mandates; an ARB can substitute for an ACE inhibitor if intolerance develops (VALIANT trial).

Option A: Option A is incorrect — amlodipine is safe post-MI and can be used for additional BP control but does not provide the mortality benefit of ACE inhibitors and beta-blockers; it is not the preferred initial choice.
Option B: Option B is incorrect — chlorthalidone does not have specific post-MI mortality benefit; it lacks the anti-remodeling and anti-arrhythmic effects of the preferred classes.
Option C: Option C is incorrect — ACE inhibitors and ARBs have equivalent post-MI evidence; ARBs are not superior; cough preference alone does not justify monotherapy when combination therapy is indicated.
Option E: Option E is incorrect — non-dihydropyridine CCBs (verapamil, diltiazem) are specifically contraindicated in post-MI patients with reduced EF due to negative inotropic effects that can worsen ventricular function.

6. A 55-year-old woman with hypertension develops bilateral ankle edema 3 months after starting amlodipine 10 mg. Her BP is well controlled at 126/78 mmHg. Cardiac evaluation shows no heart failure. Her physician considers switching to a different antihypertensive. Which of the following most accurately guides management?

A) Switch to verapamil — non-dihydropyridine CCBs provide equivalent BP control without causing peripheral edema because they have balanced arteriovenous effects
B) Add furosemide — loop diuretics directly remove the interstitial fluid causing the edema and are the preferred pharmacological treatment for CCB-induced ankle swelling
C) The edema is hemodynamically mediated through precapillary arteriolar dilation without equivalent venodilation — management options include: adding an ACE inhibitor or ARB (which counteract CCB edema through venodilation and have shown reduced edema rates in the ACCOMPLISH trial combination), reducing the amlodipine dose if BP allows, compression stockings, or switching CCBs; furosemide is not the preferred approach as it does not address the underlying hemodynamic mechanism and risks volume depletion
D) Switch to nifedipine immediate-release — short-acting dihydropyridines cause less peripheral edema than long-acting amlodipine because the shorter duration of arteriolar dilation allows more frequent venous pressure normalization
E) Discontinue all antihypertensives — the edema indicates systemic fluid overload that will resolve only when all BP medications causing vasodilation are stopped

ANSWER: C

Rationale:

CCB-induced peripheral edema is hemodynamic in origin — arteriolar dilation increases capillary hydrostatic pressure in dependent tissues without equivalent venodilation; management should address the mechanism rather than treat the edema symptomatically with diuretics; adding a RAAS inhibitor (ACE inhibitor or ARB) is the pharmacologically rational approach — RAAS inhibitors dilate venules, reducing the arteriolar-venous pressure gradient that drives fluid transudation; the ACCOMPLISH trial used the benazepril-amlodipine combination which had lower edema rates than expected for amlodipine monotherapy; dose reduction or switching to another CCB are alternatives if BP allows.

Option A: Option A is incorrect — verapamil does reduce CCB edema compared to dihydropyridines due to more balanced arteriovenous effects, but switching from a well-tolerated antihypertensive with good BP control introduces new risks (negative inotropy, drug interactions, constipation) without addressing the fundamental issue; verapamil is contraindicated if HFrEF is present.
Option B: Option B is incorrect — furosemide treats the edema symptomatically but does not address the underlying hemodynamic mechanism; it risks volume depletion, electrolyte disturbance, and reflex RAAS activation without a mechanistic rationale.
Option D: Option D is incorrect — nifedipine immediate-release is actually more likely to cause edema than amlodipine due to its rapid onset causing pronounced arteriolar dilation; short-acting dihydropyridines are generally not preferred for hypertension.
Option E: Option E is incorrect — the edema is not a sign of systemic fluid overload; it is localized hemodynamic edema; discontinuing antihypertensives would leave BP uncontrolled.

7. A 63-year-old man with hypertension and type 2 diabetes is on metformin and sitagliptin. His BP is 162/94 mmHg. He has no albuminuria (ACR 18 mg/g) and eGFR is 74 mL/min. Which of the following most accurately describes initial antihypertensive drug selection in a diabetic patient without nephropathy?

A) ACE inhibitors or ARBs are mandatory as the first antihypertensive in all diabetic patients regardless of albuminuria status — the potential for future nephropathy development justifies RAAS inhibition in every diabetic hypertensive
B) Beta-blockers should be avoided entirely in type 2 diabetes because they mask all hypoglycemic symptoms and cause severe undetected hypoglycemia in all diabetic patients on any glucose-lowering therapy
C) Thiazide diuretics are absolutely contraindicated in type 2 diabetes because they invariably cause uncontrollable hyperglycemia that negates the cardiovascular benefit of BP reduction
D) Dihydropyridine CCBs are contraindicated in type 2 diabetes because calcium channel blockade impairs glucose-stimulated insulin secretion from pancreatic beta cells
E) Any first-line class — thiazide diuretics, ACE inhibitors, ARBs, or dihydropyridine CCBs — is appropriate for initial therapy in a diabetic patient without nephropathy; the primary goal is BP reduction; RAAS inhibitors are preferred by many guidelines when albuminuria develops but without albuminuria the evidence for their superiority over other classes is less compelling; metabolic considerations favor avoiding high-dose thiazides which can worsen glucose tolerance

ANSWER: E

Rationale:

In a diabetic patient without albuminuria, current guidelines allow any first-line antihypertensive class — the primary therapeutic goal is BP reduction, and all major classes (thiazides, ACE inhibitors, ARBs, CCBs) reduce cardiovascular events when BP is controlled; RAAS inhibitors become the preferred class when albuminuria develops (ACR ≥30 mg/g) due to their renoprotective benefit beyond BP lowering; without albuminuria, the evidence does not establish RAAS inhibitor superiority for this patient; high-dose thiazides can worsen glucose tolerance and dyslipidemia, so lower doses (chlorthalidone 12.5–25 mg) are preferred when used in diabetes.

Option A: Option A is incorrect — guidelines do not mandate RAAS inhibitors in all diabetic hypertensives regardless of albuminuria; the compelling indication for RAAS inhibition is nephropathy with albuminuria, not diabetes alone.
Option B: Option B is incorrect — beta-blockers are not absolutely contraindicated in diabetes; they do blunt some hypoglycemic symptoms (tachycardia, tremor) but not diaphoresis; cardioselective beta-blockers are used cautiously when indicated; the statement that they cause severe undetected hypoglycemia in all diabetic patients is an overstatement.
Option D: Option D is incorrect — dihydropyridine CCBs do not impair insulin secretion at therapeutic doses; they are safe and commonly used in diabetic hypertensive patients.
Option C: Option C is incorrect — thiazides can modestly worsen glucose tolerance but are not absolutely contraindicated; at appropriate doses they are used in diabetic hypertension; the ALLHAT trial included large numbers of diabetic patients treated with chlorthalidone.

8. A 58-year-old woman with hypertension is started on lisinopril 5 mg. At her 2-week follow-up her creatinine has risen from 0.9 to 1.3 mg/dL (a 44% increase). She has no symptoms and her BP is 128/76 mmHg. Which of the following most accurately guides management of this creatinine rise?

A) Discontinue lisinopril immediately and permanently — any creatinine rise on an ACE inhibitor indicates irreversible renal damage and the drug must never be used again
B) A creatinine rise of up to 30% above baseline after initiating an ACE inhibitor or ARB is generally acceptable and reflects the expected reduction in intraglomerular pressure from efferent arteriolar dilation; a 44% rise is above this threshold and warrants investigation — check for volume depletion, concurrent NSAID use, or underlying bilateral renal artery stenosis; if no reversible cause is found and the rise exceeds 30–35%, dose reduction or temporary discontinuation may be needed pending further evaluation
C) The creatinine rise confirms the drug is working correctly — larger rises indicate greater intraglomerular pressure reduction and better renoprotection; no action is needed
D) Add a loop diuretic to increase renal perfusion pressure and reverse the creatinine rise while continuing lisinopril at the same dose
E) Switch to an ARB — ARBs do not cause creatinine rises because they block the receptor rather than the enzyme, preserving enough efferent arteriolar tone to maintain GFR

ANSWER: B

Rationale:

A creatinine rise of up to 30% above baseline after initiating RAAS inhibition is generally acceptable and expected — it reflects reduced intraglomerular pressure from efferent arteriolar dilation, which is the desired renoprotective mechanism; rises above 30–35% warrant investigation for reversible contributing factors: volume depletion (concurrent diuretic use, poor oral intake), NSAID use (which blunts afferent arteriolar dilation that normally compensates), or bilateral renal artery stenosis (where efferent arteriolar tone is critical for maintaining GFR in both kidneys); a 44% rise should prompt this investigation before deciding on drug continuation; if no reversible cause is found, dose reduction or temporary discontinuation may be appropriate.

Option A: Option A is incorrect — a creatinine rise does not indicate irreversible renal damage; it reflects the hemodynamic mechanism of RAAS inhibition and is often reversible; permanent discontinuation for any creatinine rise is too aggressive.
Option C: Option C is incorrect — while some creatinine rise is expected and acceptable, a 44% rise is above the acceptable threshold and requires evaluation; it does not indicate greater renoprotection.
Option D: Option D is incorrect — adding furosemide to increase renal perfusion would address volume depletion if present, but this should be part of a diagnostic evaluation, not an empirical intervention while continuing the same dose; the volume status must first be assessed.
Option E: Option E is incorrect — ARBs cause equivalent creatinine rises through the same mechanism of efferent arteriolar dilation; switching classes does not resolve the issue.

9. A 70-year-old man with hypertension is on chlorthalidone 25 mg. His routine labs show sodium 128 mEq/L. He is mildly confused. Which of the following most accurately explains the mechanism and guides management?

A) The hyponatremia is caused by chlorthalidone-induced aldosterone excess — the drug stimulates adrenal aldosterone secretion which causes free water retention through a mineralocorticoid-mediated mechanism independent of sodium reabsorption
B) Chlorthalidone-induced hyponatremia results from impaired urinary dilution in the distal convoluted tubule combined with non-osmotic ADH release from volume contraction — NCC blockade prevents free water excretion in the diluting segment; volume depletion stimulates ADH release causing collecting duct free water reabsorption; the net result is dilutional hyponatremia; chlorthalidone must be discontinued and sodium corrected carefully; this patient's risk factors (elderly male, likely low body water) made him susceptible; correction must not exceed 8–10 mEq/L per 24 hours to avoid osmotic demyelination
C) The hyponatremia is caused by excessive sodium excretion from chlorthalidone — the drug removes so much sodium through natriuresis that total body sodium is depleted; treatment is high-dose sodium chloride infusion at a rate matching the urinary losses
D) Mild hyponatremia from thiazides is always asymptomatic and does not require drug discontinuation — the confusion is unrelated to the sodium level and an alternative cause should be sought
E) Switch to hydrochlorothiazide — the shorter half-life of hydrochlorothiazide causes less cumulative sodium excretion and the hyponatremia will self-correct without discontinuing diuretic therapy

ANSWER: B

Rationale:

Thiazide-induced hyponatremia is dilutional — NCC blockade in the distal convoluted tubule impairs the diluting segment's ability to generate free water for excretion; volume contraction from natriuresis causes non-osmotic ADH release which drives collecting duct free water reabsorption; the result is free water retention and dilutional hyponatremia; elderly patients with low total body water are at highest risk; sodium of 128 mEq/L with confusion indicates symptomatic hyponatremia requiring chlorthalidone discontinuation and careful sodium correction — the rate of correction must not exceed 8–10 mEq/L per 24 hours to avoid osmotic demyelination syndrome.

Option A: Option A is incorrect — thiazide-induced hyponatremia is not mediated by aldosterone excess; the mechanism is impaired urinary dilution and non-osmotic ADH release as described.
Option C: Option C is incorrect — the hyponatremia is dilutional from free water retention, not from sodium depletion exceeding intake; aggressive sodium replacement without addressing the free water excess could worsen the situation.
Option D: Option D is incorrect — sodium of 128 mEq/L with confusion is symptomatic hyponatremia requiring intervention; attributing the confusion to an alternative cause without addressing the sodium is inappropriate.
Option E: Option E is incorrect — switching to hydrochlorothiazide would continue the same mechanism of NCC blockade causing impaired urinary dilution; the shorter half-life does not protect against hyponatremia development; discontinuation of the thiazide is required.

10. A 66-year-old woman with hypertension and paroxysmal atrial fibrillation (AF) requiring rate control has BP of 154/92 mmHg. She is currently on warfarin. Which antihypertensive class serves dual purpose for both BP control and AF rate control?

A) Non-dihydropyridine CCBs (verapamil or diltiazem) or beta-blockers — both classes slow AV nodal conduction, reducing the ventricular rate response in AF; beta-blockers block sympathetic drive to the AV node while non-dihydropyridine CCBs block calcium-dependent AV nodal conduction; either class provides dual benefit for rate control and BP; the choice between them depends on LV function — non-dihydropyridine CCBs are contraindicated in HFrEF
B) Thiazide diuretics — volume reduction lowers ventricular filling pressure and reduces the ventricular rate response to AF through a preload-dependent mechanism
C) ACE inhibitors — they reduce atrial fibrosis through RAAS blockade, converting AF to sinus rhythm while simultaneously lowering BP
D) Dihydropyridine CCBs — amlodipine provides rate control in AF through its vascular selectivity which reduces afterload and secondarily reduces the ventricular rate through baroreceptor-mediated AV nodal slowing
E) ARBs — AT1 receptor blockade in the atrial myocardium prevents structural remodeling that perpetuates AF while simultaneously lowering BP through RAAS inhibition

ANSWER: A

Rationale:

Beta-blockers and non-dihydropyridine CCBs are the two drug classes used for ventricular rate control in AF — beta-blockers (metoprolol, atenolol, carvedilol) block sympathetic drive to the AV node, slowing conduction and reducing ventricular rate; non-dihydropyridine CCBs (verapamil, diltiazem) block L-type calcium channels in AV nodal cells, slowing calcium-dependent conduction; both provide dual benefit of rate control and BP reduction; the critical distinction is LV function — non-dihydropyridine CCBs are contraindicated in HFrEF due to negative inotropy; digoxin is an alternative for rate control but does not lower BP.

Option C: Option C is incorrect — ACE inhibitors do not provide AV nodal rate control; while they may have some role in preventing AF recurrence through atrial anti-remodeling effects, they do not acutely control ventricular rate.
Option B: Option B is incorrect — thiazide diuretics have no AV nodal effects and do not provide rate control in AF.
Option D: Option D is incorrect — dihydropyridine CCBs have minimal cardiac electrophysiological effects due to their vascular selectivity; amlodipine does not slow AV nodal conduction and does not provide rate control in AF; using it for this purpose is pharmacologically incorrect.
Option E: Option E is incorrect — ARBs have been studied for AF prevention (upstream therapy) but do not provide acute ventricular rate control in established AF.

11. A 52-year-old man with hypertension and recurrent calcium oxalate nephrolithiasis has BP of 158/96 mmHg. He passes approximately 2 kidney stones per year. Which antihypertensive class offers a specific secondary benefit for his nephrolithiasis?

A) ACE inhibitors — they reduce urinary calcium excretion through efferent arteriolar dilation that lowers filtration fraction and calcium delivery to the tubule
B) Beta-blockers — beta-1 blockade reduces renin-mediated aldosterone secretion, lowering urinary calcium excretion through reduced calcium-sodium exchange in the distal tubule
C) Thiazide diuretics — they enhance calcium reabsorption in the distal convoluted tubule through a mechanism linked to NCC blockade; reduced urinary calcium excretion (hypocalciuria) decreases calcium oxalate supersaturation in the urine, reducing stone formation; this is an established secondary indication for thiazides in hypercalciuric nephrolithiasis
D) Dihydropyridine CCBs — L-type calcium channel blockade in the renal tubule reduces calcium reabsorption, paradoxically lowering serum calcium and reducing the calcium available for stone formation
E) ARBs — AT1 receptor blockade prevents angiotensin II-mediated proximal tubular calcium reabsorption, reducing the calcium delivered to the distal nephron where stones form

ANSWER: C

Rationale:

Thiazide diuretics are the antihypertensive class with established benefit in calcium oxalate nephrolithiasis — NCC blockade in the distal convoluted tubule creates a sodium gradient that enhances active calcium reabsorption in that segment; the resulting hypocalciuria (reduced urinary calcium excretion) decreases calcium oxalate supersaturation in the urine, reducing stone formation; hydrochlorothiazide and chlorthalidone are both used for this indication; this patient with hypertension and recurrent calcium stones is an ideal candidate where one drug addresses both conditions.

Option A: Option A is incorrect — ACE inhibitors do not have established benefit for calcium nephrolithiasis; efferent arteriolar dilation changes filtration dynamics but does not produce clinically meaningful hypocalciuria.
Option B: Option B is incorrect — beta-blockers do not reduce urinary calcium excretion through the mechanism described; they are not used for nephrolithiasis prevention.
Option D: Option D is incorrect — dihydropyridine CCBs block calcium channels in vascular smooth muscle, not renal tubular cells; they do not reduce urinary calcium excretion and are not used for nephrolithiasis.
Option E: Option E is incorrect — ARBs do not have established benefit for calcium nephrolithiasis through the mechanism described; proximal tubular calcium reabsorption via angiotensin II is not a primary driver of hypercalciuria in stone formers.

12. A 59-year-old man with hypertension, hyperlipidemia, and peripheral arterial disease (PAD) of the lower extremities has BP of 160/96 mmHg. He has claudication after walking two blocks. Which of the following most accurately describes the antihypertensive considerations specific to his PAD?

A) Non-selective beta-blockers are absolutely contraindicated in all PAD patients because beta-2 blockade in peripheral vascular smooth muscle causes severe vasoconstriction that will precipitate critical limb ischemia
B) Dihydropyridine CCBs are contraindicated in PAD because peripheral vasodilation diverts blood flow away from ischemic muscle beds through a vascular steal mechanism
C) ACE inhibitors are contraindicated in PAD because the reduction in angiotensin II removes a vasoconstrictive signal that is critical for maintaining perfusion pressure in stenotic peripheral vessels
D) Non-selective beta-blockers should be avoided in symptomatic PAD — beta-2 blockade in peripheral vascular smooth muscle reduces vasodilatory tone and can worsen claudication; cardioselective beta-blockers are safer but should still be used cautiously; ACE inhibitors and dihydropyridine CCBs are appropriate choices and CCBs may improve peripheral perfusion through direct vasodilation; the HOPE trial demonstrated that ramipril reduced cardiovascular events in PAD patients
E) All antihypertensives are relatively contraindicated in PAD because any BP reduction reduces perfusion pressure distal to the stenosis and worsens ischemia — the BP should be maintained above 160 mmHg systolic to ensure adequate peripheral perfusion

ANSWER: D

Rationale:

Non-selective beta-blockers worsen claudication in symptomatic PAD through beta-2 blockade in peripheral vascular smooth muscle — this reduces vasodilatory tone in the already-compromised peripheral circulation and can worsen symptoms; however, they are not absolutely contraindicated and may be used when a compelling indication exists (post-MI, HFrEF) with the understanding that claudication may worsen; cardioselective beta-blockers (metoprolol, bisoprolol) are safer but selectivity is not complete; ACE inhibitors are appropriate and beneficial — the HOPE trial demonstrated that ramipril significantly reduced cardiovascular events in patients with PAD; dihydropyridine CCBs are appropriate and may improve peripheral perfusion through direct vasodilation of peripheral vessels.

Option A: Option A is incorrect — while non-selective beta-blockers can worsen claudication, they are not absolutely contraindicated in all PAD patients; the absolute contraindication language is too strong and the risk is of worsened claudication, not acute critical limb ischemia in typical PAD.
Option B: Option B is incorrect — dihydropyridine CCBs are not contraindicated in PAD; peripheral vasodilation through a steal mechanism causing worsening ischemia is not an established clinical concern with CCBs in PAD.
Option C: Option C is incorrect — ACE inhibitors are beneficial in PAD, not contraindicated; the HOPE trial specifically demonstrated cardiovascular benefit in this population.
Option E: Option E is incorrect — untreated hypertension causes progressive atherosclerosis worsening PAD over time; the cardiovascular risk of uncontrolled hypertension far outweighs any theoretical perfusion benefit of elevated BP.

13. A 44-year-old woman with hypertension is well-controlled on losartan 50 mg. She develops bilateral leg edema, fatigue, and dyspnea on exertion over 6 weeks. Echocardiogram shows new HFrEF with EF 30%. Which change to her antihypertensive regimen is most appropriate?

A) Discontinue losartan — ARBs are contraindicated in HFrEF because AT1 receptor blockade eliminates the compensatory angiotensin II effect that maintains contractility in the failing heart
B) Continue losartan and add amlodipine — dihydropyridine CCBs are specifically indicated in HFrEF for their afterload-reducing benefit and the combination with an ARB provides superior BP control
C) Switch losartan to an ACE inhibitor and add diltiazem for additional afterload reduction in HFrEF
D) Switch losartan to verapamil for superior rate control and afterload reduction in the failing heart
E) Continue losartan (which now serves dual purpose as both antihypertensive and HFrEF therapy) and add a beta-blocker titrated slowly from a low dose — ARBs have mortality benefit in HFrEF (CHARM-Alternative, Val-HeFT) and are indicated when ACE inhibitors are not tolerated; beta-blockers have established HFrEF mortality benefit and should be initiated at low dose and titrated upward as tolerated; loop diuretics may be needed for volume management

ANSWER: E

Rationale:

Losartan should be continued — ARBs are indicated in HFrEF as alternatives to ACE inhibitors when the latter are not tolerated (candesartan in CHARM-Alternative, valsartan in Val-HeFT demonstrated mortality benefit); losartan is already established and well-tolerated, making it the logical continuation; a beta-blocker should be added for HFrEF mortality benefit (carvedilol in COPERNICUS, metoprolol succinate in MERIT-HF, bisoprolol in CIBIS-II) — initiated at low dose and titrated slowly in stable patients; loop diuretics address volume overload symptoms.

Option A: Option A is incorrect — ARBs are not contraindicated in HFrEF; they are a cornerstone therapy with proven mortality benefit as alternatives to ACE inhibitors.
Option B: Option B is incorrect — amlodipine is safe in HFrEF (PRAISE trials) but is not specifically indicated for mortality benefit; it can be used for additional BP control but adding it without adding a beta-blocker misses the most important therapeutic addition.
Option D: Option D is incorrect — verapamil is specifically contraindicated in HFrEF with reduced EF due to its significant negative inotropic effects; it would worsen the cardiomyopathy.
Option C: Option C is incorrect — while switching to an ACE inhibitor is reasonable if ARB is not clearly preferred, adding diltiazem (a non-dihydropyridine CCB) to HFrEF is specifically contraindicated due to negative inotropic effects.

14. A 57-year-old man with hypertension is started on metoprolol succinate 50 mg daily. At follow-up his BP is 144/88 mmHg and his resting heart rate is 58 bpm. He feels fatigued and reports cold extremities. Which of the following most accurately explains the cold extremities and guides management?

A) The cold extremities are caused by metoprolol-induced hypotension reducing peripheral perfusion — the drug should be discontinued and replaced with a vasodilating antihypertensive
B) Cold extremities from metoprolol reflect residual beta-2 receptor blockade despite its cardioselectivity — beta-2 receptors in peripheral vascular smooth muscle normally mediate vasodilation; even cardioselective beta-blockers have partial beta-2 blockade at higher doses, reducing peripheral vasodilatory tone; if the symptom is bothersome, dose reduction, switching to nebivolol (which has vasodilatory properties through NO release), or adding a dihydropyridine CCB for peripheral vasodilation are options
C) Cold extremities indicate that metoprolol has caused peripheral arterial spasm requiring emergency vasodilator therapy with IV nitroprusside
D) Cold extremities from beta-blockers are caused by alpha-1 receptor upregulation in response to beta blockade — adding an alpha-1 blocker such as prazosin is the appropriate pharmacological countermeasure
E) The cold extremities and fatigue confirm that metoprolol is causing critical cardiac output reduction — the drug must be stopped immediately before cardiac output falls further

ANSWER: B

Rationale:

Cold extremities is a recognized adverse effect of beta-blockers including cardioselective agents — beta-2 receptors in peripheral vascular smooth muscle mediate vasodilation; even cardioselective beta-1 blockers have partial beta-2 blockade, particularly at higher doses, reducing peripheral vasodilatory tone and causing cool extremities; the symptom is common, not dangerous, and is distinct from critical ischemia; management options include dose reduction if BP allows, switching to nebivolol (which releases nitric oxide causing direct peripheral vasodilation, partially counteracting the reduced beta-2 tone), or adding a dihydropyridine CCB for peripheral vasodilation; the resting HR of 58 and residual hypertension suggest the dose may need optimization regardless.

Option A: Option A is incorrect — cold extremities from beta-blockers are not caused by hypotension; his BP of 144/88 mmHg confirms adequate perfusion pressure; peripheral vasoconstriction from reduced beta-2 tone is the mechanism.
Option C: Option C is incorrect — peripheral arterial spasm requiring emergency IV therapy is a grossly inappropriate interpretation of a common, mild beta-blocker side effect.
Option D: Option D is incorrect — alpha-1 receptor upregulation is not the established mechanism of beta-blocker-induced cold extremities; adding prazosin is not the standard approach and would risk orthostatic hypotension.
Option E: Option E is incorrect — a resting HR of 58 bpm in a hypertensive patient on a beta-blocker is expected and not indicative of critical cardiac output reduction; cold extremities alone do not indicate hemodynamic compromise.

15. A 68-year-old woman with hypertension, osteoporosis, and a history of two fragility fractures is being evaluated for antihypertensive therapy. Her BP is 156/90 mmHg. Which of the following most accurately describes a pharmacological consideration specific to her bone health?

A) ACE inhibitors should be avoided in osteoporosis because they reduce parathyroid hormone secretion through RAAS-mediated calcium signaling, worsening bone turnover
B) Beta-blockers are the preferred antihypertensive in osteoporosis — beta-2 receptors on osteoblasts normally inhibit bone formation, so beta-blockade disinhibits osteoblast activity and improves bone density
C) Thiazide diuretics enhance calcium reabsorption in the distal tubule, reducing urinary calcium excretion — the resulting positive calcium balance may help preserve bone density; observational studies suggest lower fracture rates in thiazide users; selecting a thiazide diuretic as part of her antihypertensive regimen offers potential dual benefit for both BP control and bone health
D) Dihydropyridine CCBs are specifically contraindicated in osteoporosis because L-type calcium channel blockade in osteoblasts impairs the calcium signaling required for bone matrix mineralization
E) Loop diuretics should replace thiazides in osteoporotic patients — loop diuretics cause hypercalciuria that mobilizes calcium from bone into the circulation, providing calcium for ongoing bone remodeling

ANSWER: C

Rationale:

Thiazide diuretics reduce urinary calcium excretion (hypocalciuria) through enhanced calcium reabsorption in the distal convoluted tubule — this positive effect on calcium balance may help preserve bone mineral density; multiple observational studies have shown lower hip fracture rates in patients taking thiazides; while the evidence is not from randomized fracture endpoint trials, the biological plausibility and observational consistency support considering a thiazide as part of the antihypertensive regimen in an osteoporotic patient; this is a secondary benefit that complements the primary indication for BP control.

Option A: Option A is incorrect — ACE inhibitors do not adversely affect bone through the mechanism described; they are not contraindicated in osteoporosis.
Option B: Option B is incorrect — while there is some mechanistic interest in beta-blockers and bone (beta-2 receptors on osteoblasts), the clinical evidence for fracture prevention is inconsistent and beta-blockers are not recommended for osteoporosis treatment; this is not an established antihypertensive selection criterion.
Option D: Option D is incorrect — dihydropyridine CCBs are not contraindicated in osteoporosis; osteoblast calcium channel blockade causing impaired mineralization is not an established clinical concern at therapeutic doses.
Option E: Option E is incorrect — loop diuretics cause hypercalciuria (increased urinary calcium excretion) which has the opposite effect — increasing calcium loss and potentially worsening osteoporosis; they are specifically less preferred than thiazides in patients with osteoporosis or nephrolithiasis.

16. A 62-year-old man with hypertension is on lisinopril 20 mg and amlodipine 10 mg. His BP remains 152/94 mmHg. He has no diabetes, no CKD, no heart failure, and no prior MI. His potassium is 4.0 mEq/L. Which of the following most accurately describes the next pharmacological step?

A) Double the lisinopril dose to 40 mg — maximizing the ACE inhibitor before adding a third agent is always the correct approach regardless of the clinical context
B) Add a beta-blocker as the third agent — beta-blockers are the guideline-recommended third-line agent for all patients with uncontrolled hypertension on two drugs regardless of comorbidities
C) Add spironolactone 25 mg — mineralocorticoid receptor antagonism is the preferred third agent in all patients on two-drug therapy because unrecognized primary aldosteronism is the universal cause of treatment resistance
D) Switch amlodipine to verapamil — non-dihydropyridine CCBs provide superior BP lowering at equivalent doses and the switch will achieve BP control without adding a third drug
E) Add chlorthalidone 12.5–25 mg as the third agent — the combination of ACE inhibitor, dihydropyridine CCB, and thiazide diuretic is the evidence-based three-drug regimen for resistant or difficult-to-control hypertension; the ACCOMPLISH trial demonstrated that the ACE inhibitor plus CCB backbone is superior to ACE inhibitor plus thiazide for cardiovascular outcomes, supporting the addition of chlorthalidone to this existing two-drug regimen; his potassium of 4.0 mEq/L provides comfortable margin for thiazide-induced hypokalemia

ANSWER: E

Rationale:

Adding chlorthalidone is the appropriate third agent — this patient is on the evidence-based ACE inhibitor plus dihydropyridine CCB backbone (supported by ACCOMPLISH); adding a thiazide diuretic completes the three-drug standard combination addressing three complementary mechanisms: RAAS blockade (ACE inhibitor), direct vasodilation (CCB), and volume reduction (thiazide); his potassium of 4.0 mEq/L provides adequate margin for thiazide-associated hypokalemia; chlorthalidone is preferred over hydrochlorothiazide for its longer half-life and superior outcome trial evidence (ALLHAT, SHEP).

Option A: Option A is incorrect — while maximizing one drug before adding another is sometimes appropriate, lisinopril 20 mg is already at a clinically effective dose; doubling to 40 mg provides modest additional BP reduction with increased side effect risk; adding a complementary-mechanism drug is generally more effective.
Option C: Option C is incorrect — spironolactone is an evidence-based fourth agent in resistant hypertension (PATHWAY-2 trial) but this patient is on only two agents and has no evidence of primary aldosteronism; empirical spironolactone as a universal third agent is not guideline-supported.
Option D: Option D is incorrect — verapamil does not provide superior BP lowering compared to amlodipine at equivalent antihypertensive doses; switching CCBs would also introduce negative inotropic risk and drug interaction concerns without the benefit of addressing a new mechanism.
Option B: Option B is incorrect — beta-blockers are not the guideline-recommended universal third-line agent; they are appropriate when a compelling indication exists (post-MI, HFrEF, AF rate control) but in uncomplicated hypertension the thiazide addition to complete the ACE+CCB+thiazide triple is more evidence-based.